Comprehensive CTC Analysis

CTCELLS enhances precision oncology by adding critical value to existing ctDNA liquid biopsies, filling in biological gaps with whole-cell data to enable a truly comprehensive analysis. The company's science centers on the CTCeptor platform, which utilizes Continuous Centrifugal Microfluidics (CCM) and a negative selection process to fully automate the isolation of both circulating tumor cells (CTCs) and circulating Cancer-Associated Fibroblasts (cCAFs). Paired with a proprietary hydrogel-based lossless staining technology, this platform ensures the recovery of highly pure, viable cells to provide a complete picture of not only the tumor itself, but also its complex tumor microenvironment (TME). Operating as a specialized service provider for pharmaceutical companies, CTCELLS leverages these dual-isolation capabilities to support advanced drug development, novel biomarker validation, and real-time therapeutic response tracking.